



IVCC Stakeholder Meeting

Interceptor® G2 Partnering for Impact

Achim Reddig - BASF Global Public Health
September 2019



Source: James Patrick (JC Flowers Foundation - Namibia 2018)

Our Mission

- Be socially responsible
- Save lives through BASF products and technology
- Innovate to improve quality of life for the poorest and most vulnerable
- Business needs to be profitable



The Board of Executive Directors of BASF SE



Dr. Martin Brudermüller
Chairman



Dr. Hans-Ulrich Engel
Vice Chairman



Saori Dubourg



Sanjeev Gandhi



Michael Heinz



Dr. Markus Kamieth



Wayne T. Smith

 **BASF Public Health has full support from Board members**

BASF Global Public Health

- an integral part of the Agricultural Solutions division



Chemicals

Petrochemicals

Monomers

Intermediates



Performance Products

Dispersions & Pigments

Care Chemicals

Nutrition & Health

Performance Chemicals



Functional Materials & Solutions

Catalysts

Construction Chemicals

Coatings

Performance Materials




Agricultural Solutions

Agricultural Solutions

➔ BASF Global Public Health benefits from the synergies of a broad technology portfolio

BASF Agricultural Solutions

- an integral part of the BASF Group




* Before special items

- ➡ R&D investment in Agricultural Solutions is higher than in any other division
- ➡ BASF Public Health is subsidized by Agricultural Solutions


Our Approach to Public Health

Innovation to prevent vector-borne diseases



Prevention

BASF's public health products - long-lasting insecticide-treated mosquito nets, indoor residual wall sprays and larvicides - protect people, day and night from the mosquitoes that spread disease.



Interceptor® nets



Fendona® indoor residual sprays



Abate® larvicides



Partnership

BASF partners with development and aid organizations that are trying to put an end to vector-borne disease and improve health systems in countries affected by these debilitating illnesses.



Product Innovation


Mosquitoes are becoming resistant to existing insecticides. BASF is launching a new generation of products to combat mosquito-borne disease.

Malaria Today no one has to die from malaria. It is preventable and treatable. Read more	
Dengue Fever Estimated 390 million dengue infections each year. Read more	
Guinea Worm Set to become only the second disease to be eradicated in human history. Read more	
Yellow Fever Infection levels on the increase. Read more	
Zika virus – WHO declares public health emergency Read more	

➔ **BASF Public Health provides an innovative and integrated portfolio**

Interceptor® G2

Project development



- Significant price decrease for LLINs since 2010
- Increasing volume of LLIN deliveries worldwide
- Strategic concentration of aid organization procurement


development to launch of Interceptor G2

- ➡ Key planning assumptions, price and registration timelines changed since project start
- ➡ KPIs for R&D projects are more challenging to meet

Interceptor® G2

A dual a.i. LLIN with the new active ingredient Chlorfenapyr


- Interceptor® G2 is a :
 - ▶ LN coated with 200 mg/m² chlorfenapyr and 100 mg/m² alpha-cypermethrin
 - ▶ LN with a novel insecticide with a new MoA in combination with a pyrethroid to kill insecticide resistant mosquitoes



➡ Those resources to develop Interceptor G2 have been crucial for success

Interceptor® G2

Experimental hut trials – Burkina Faso



- Burkina Faso has documented increasing levels of insecticide resistance in malaria vectors
- Standard pyrethroid-only LLINs show a mortality rate of approx. 20%
- Interceptor® G2 shows a mortality rate of:
 - 81% for unwashed LLINs
 - 79% after 20 washes
- Interceptor® G2 is highly effective against insecticide resistant mosquitos
- Long-lasting efficacy

Bayili K., N'do S., Namountougou M., Sanou R., Ouattara A., Dabiré R. K., Ouédraogo G. A., Malone D., Diabaté A. (2017) Evaluation of efficacy of Interceptor® G2, a long-lasting insecticide net coated with a mixture of chlorfenapyr and alpha-cypermethrin, against pyrethroid resistant *Anopheles gambiae* sl in Burkina Faso, Malar J. 16:190

Interceptor® G2

Status



Malaria Summit London 2018: Bill Gates presents Interceptor® G2 as a new innovative tool to fight malaria

- Commitment to the “Zero by 40” initiative to end malaria by 2040
- Endorsed by Bill Gates at the 2018 London Malaria Summit
- Current status:
 - WHOPES interim recommendation granted and PQ-listed
 - WHO VCAG noted: *“Interceptor® G2 outperformed Interceptor® LN (washed and unwashed) in terms of its killing effect against pyrethroid-resistant mosquitoes in laboratory and experimental hut studies.”*
 - First RCT trial started in Tanzania
 - Second RCT trial in Benin planned

Interceptor® G2

UNITAID/Global Fund New Net Project Status



Standard bag artwork (front-side) of Interceptor® G2

- BASF and IVCC have signed agreement under Catalytic Funding Project
- Catalytic LLIN Partnership Initiative by:



Planned deliveries for pilot trials:

2019

- Burkina Faso
- Rwanda
- Mali


2020

- Mozambique
- Uganda
- tbd.

➡ Strong support from partners is crucial for success!!!

BASF Public Health

Path forward



The innovative new Interceptor® G2 mosquito net is recognizable by its distinctive striped pattern

- Build on strong partnership with Bill & Melinda Gates Foundation, CHAI, President's Malaria Initiative, The Global Fund and IVCC
- Invest in insecticide resistance breaking technology (Interceptor® G2 and Sylando)
- Evaluate further technologies from insecticide pipeline and third parties
- Maintain highest production standards

Please visit our Public Health homepage:

www.publichealth.basf.com





We create chemistry